Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

4,060.00p
   
  • Change Today:
    -25.00p
  • 52 Week High: 4,114.00
  • 52 Week Low: 3,040.00
  • Currency: UK Pounds
  • Shares Issued: 5.14m
  • Volume: 2,737
  • Market Cap: £208.79m

Bioventix ups dividend on improved profits

By Iain Gilbert

Date: Monday 26 Mar 2018

LONDON (ShareCast) - (ShareCast News) - AIM-quoted pharmaceuticals company Bioventix saw revenues and profits move ahead in the first half of its trading year, leading the company to boost its first interim dividend by 20%.
Underlying revenues at Bioventix grew 13% to £3.5m, thanks in no small part to an improved performance in the "important emerging market" that is China, pushing pre-tax profits up 36% to £3.4m as a result.

During the half, an internal audit undertaken by one of Bioventix's customers identified a back-dated royalty stream of £772,391, owed to the firm for work completed between 1 July 2014 to 30 June 2017 and therefore, outside the current reporting period.

Vitamin D antibody sales continued at the same healthy levels seen in the last half of its previous trading year and gained approximately £400,000 year-on-year.

Growth in other antibody sales, such as progesterone, drug antibodies, contract NT-proBNP, also amounted to roughly £400,000, meaning the combined effect of the improved sales was "more than sufficient" to make up for the £400,000 of revenue lost due to a previously reported terminated revenue stream.

For the six months ended 31 December, Bioventix announced a first interim dividend of 25p.

"We are pleased with the continued success of our vitamin D antibody and the remainder of the core antibody business. We remain optimistic about our troponin project and the success of Siemens as their product launches around the world and we look forward to further progress in the second half of the year," said chief executive Peter Harrison on Monday.

As of 1020 GMT, shares had collected 12.90% to 2,320p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 4,060.00p
Change Today -25.00p
% Change -0.61 %
52 Week High 4,114.00
52 Week Low 3,040.00
Volume 2,737
Shares Issued 5.14m
Market Cap £208.79m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
97.31% below the market average97.31% below the market average97.31% below the market average97.31% below the market average97.31% below the market average
89.47% below the sector average89.47% below the sector average89.47% below the sector average89.47% below the sector average89.47% below the sector average
Price Trend
75.82% above the market average75.82% above the market average75.82% above the market average75.82% above the market average75.82% above the market average
71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average
Income
68.89% below the market average68.89% below the market average68.89% below the market average68.89% below the market average68.89% below the market average
Sector averageSector averageSector averageSector averageSector average
Growth
8.04% above the market average8.04% above the market average8.04% above the market average8.04% above the market average8.04% above the market average
40.54% above the sector average40.54% above the sector average40.54% above the sector average40.54% above the sector average40.54% above the sector average

Bioventix Dividends

  Latest Previous
  Final Special
Ex-Div 31-Oct-19 31-Oct-19
Paid 15-Nov-19 15-Nov-19
Amount 43.00p 47.00p

Trades for 21-Jan-2020

Time Volume / Share Price
15:24 122 @ 4,095.00p
15:07 36 @ 4,095.00p
15:01 123 @ 4,017.00p
14:47 95 @ 4,017.00p
14:34 40 @ 4,007.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
Finance Director Treena Joan Turner

Top of Page